5HVF

Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-i83)

5HVF の概要

• エントリーDOI: 10.2210/pdb5hvf/pdb
• 関連するPDBエントリー: 5HVG 5HVH
• 分子名称: Carboxypeptidase B2, VHH-i83, alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (7 entities in total)
• 機能のキーワード: procarboxypeptidase u, thrombin-activatable fibrinolysis inhibitor, tafi, procarboxypeptidase r, plasma procarboxypeptidase b, nanobody, antibody fragment, protein complex, hydrolase/hydrolase inhibitor, hydrolase, hydrolase-hydrolase inhibitor complex
• 由来する生物種: Homo sapiens (Human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 60624.13

構造登録者

Zhou, X.,Weeks, S.D.,Strelkov, S.V.,Declerck, P.J. (登録日: 2016-01-28, 公開日: 2016-06-22, 最終更新日: 2024-10-23)

主引用文献

Zhou, X.,Weeks, S.D.,Ameloot, P.,Callewaert, N.,Strelkov, S.V.,Declerck, P.J.
Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
J.Thromb.Haemost., 14:1629-1638, 2016

PubMed Abstract: Essentials Thrombin-activatable fibrinolysis inhibitor (TAFI) is a risk factor for cardiovascular disorders. TAFI inhibitory nanobodies represent a promising step in developing profibrinolytic therapeutics. We have solved three crystal structures of TAFI in complex with inhibitory nanobodies. Nanobodies inhibit TAFI through distinct mechanisms and represent novel profibrinolytic leads.

PubMed: 27279497
DOI: 10.1111/jth.13381

実験手法

X-RAY DIFFRACTION (2.85 Å)